Eris Lifesciences is currently trading at Rs. 701.05, up by 23.15 points or 3.41% from its previous closing of Rs. 677.90 on the BSE.
The scrip opened at Rs. 690.95 and has touched a high and low of Rs. 708.75 and Rs. 690.95 respectively. So far 157 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 896.00 on 14-Mar-2018 and a 52 week low of Rs. 571.50 on 12-Nov-2018.
Last one week high and low of the scrip stood at Rs. 708.75 and Rs. 663.90 respectively. The current market cap of the company is Rs. 9395.20 crore.
The promoters holding in the company stood at 55.92% while Institutions and Non-Institutions held 19.81% and 24.26% respectively.
Eris Lifesciences and India Medtronic, a wholly owned subsidiary of Medtronic plc, the global leader in medical technology, have collaborated for a diabetes monitoring initiative in India. The two companies will utilize their respective strengths in helping patients monitor their diabetes better.
Medtronic will bring to India its latest US Food and Drug Administration (USFDA) approved Guardian Connect device for real-time evaluation of glucose variability in diabetes patients. Eris through its national reach will provide the device at clinics and healthcare delivery units under its patient care initiative. Guardian Connect is the world's first Smart Continuous Glucose Monitoring System connected with smartphone displays for real-time data viewing of glucose levels, without a separate hardware monitor.
Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1800.30 |
Dr. Reddys Lab | 1275.05 |
Cipla | 1472.05 |
Lupin | 2098.70 |
Zydus Lifesciences | 979.10 |
View more.. |